← Oncology Approval Tracker

FDA DECISION ·

Imfinzi

durvalumab · AstraZeneca

FDA approvalNew or expanded indicationEndometrial cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with mismatch repair-deficient primary advanced or recurrent endometrial cancer; use with carboplatin and paclitaxel followed by durvalumab alone.

LAMPGEN ANALYSIS

Why it matters

The indication is confined to dMMR disease; read DUO-E results in that biomarker-defined context.

What research teams should watch

Verify the MMR result before treatment and separate the FDA-approved maintenance regimen from other DUO-E study arms.

PRIMARY RECORDS

Sources